Business Wire

Perseid Achieves Second Preclinical Milestone under Collaboration with Astellas for CTLA-4 Program

Perseid’s CTLA4-Ig product candidates (designated as MAXY-4) are designed to be superior, next-generation CTLA4-Ig therapeutics for the treatment of a broad array of autoimmune disorders, including ...
Business Wire

Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted ...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg ...
PharmiWeb

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia ...

Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and ...
FierceBiotech

Perseid Achieves Preclinical Milestone Under Collaboration with Astellas for CTLA-4 Program

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a ...